Your browser doesn't support javascript.
loading
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
Damrauer, Jeffrey S; Roell, Kyle R; Smith, Markia A; Sun, Xuezheng; Kirk, Erin L; Hoadley, Katherine A; Benefield, Halei C; Iyer, Gopakumar; Solit, David B; Milowsky, Matthew I; Kim, William Y; Nielsen, Matthew E; Wobker, Sara E; Dalbagni, Guido; Al-Ahmadie, Hikmat A; Olshan, Andrew F; Bochner, Bernard H; Furberg, Helena; Troester, Melissa A; Pietzak, Eugene J.
Afiliação
  • Damrauer JS; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Roell KR; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Smith MA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Sun X; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Kirk EL; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Hoadley KA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Benefield HC; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Iyer G; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Solit DB; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Milowsky MI; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Kim WY; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Nielsen ME; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Wobker SE; Department of Medicine (Genitourinary Oncology Service), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Dalbagni G; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Al-Ahmadie HA; Department of Medicine (Genitourinary Oncology Service), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Olshan AF; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Bochner BH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Furberg H; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • Troester MA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Pietzak EJ; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Clin Cancer Res ; 27(16): 4599-4609, 2021 08 15.
Article em En | MEDLINE | ID: mdl-34117034
ABSTRACT

PURPOSE:

Improved risk stratification and predictive biomarkers of treatment response are needed for non-muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC. EXPERIMENTAL

DESIGN:

Gene expression in NMIBC samples was profiled by NanoString nCounter, an RNA quantification platform, from two independent cohorts (n = 28, n = 50); targeted panel sequencing was performed in a subgroup (n = 50). Gene signatures were externally validated using two RNA sequencing datasets of NMIBC tumors (n = 438, n = 73). Established molecular subtype classifiers and novel gene expression signatures were assessed for associations with clinicopathologic characteristics, somatic tumor mutations, and treatment outcomes.

RESULTS:

Molecular subtypes distinguished between low-grade Ta tumors with FGFR3 mutations and overexpression (UROMOL-class 1) and tumors with more aggressive clinicopathologic characteristics (UROMOL-classes 2 and 3), which were significantly enriched with TERT promoter mutations. However, UROMOL subclasses were not associated with recurrence after bacillus Calmette-Guérin (BCG) immunotherapy in two independent cohorts. In contrast, a novel expression signature of an inflamed tumor microenvironment (TME) was associated with improved recurrence-free survival after BCG. Expression of immune checkpoint genes (PD-L1/PD-1/CTLA-4) was associated with an inflamed TME, but not with higher recurrence rates after BCG. FGFR3 mutations and overexpression were both associated with low immune signatures.

CONCLUSIONS:

Assessment of the immune TME, rather than molecular subtypes, is a promising predictive biomarker of BCG response. Modulating the TME in an immunologically "cold" tumor warrants further investigation. Integrated transcriptomic and exome sequencing should improve treatment selection in NMIBC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Vacina BCG / Adjuvantes Imunológicos / Microambiente Tumoral / Transcriptoma Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Vacina BCG / Adjuvantes Imunológicos / Microambiente Tumoral / Transcriptoma Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article